Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza mRNA Formulation A
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza mRNA Formulation A (GSK4382276A) is an investigational, multivalent mRNA-based vaccine candidate designed for the prevention of seasonal influenza. Developed by GSK in collaboration with CureVac, the vaccine is built upon CureVac's second-generation mRNA backbone and utilizes lipid nanoparticle (LNP) technology for delivery. It encodes hemagglutinin (HA) antigens matched to three WHO-recommended influenza strains, providing coverage against both influenza A and B lineages. In Phase 2a clinical trials (NCT06431607), Formulation A demonstrated positive immunogenicity and an acceptable safety and reactogenicity profile in both younger (18–64) and older (65–85) adults. These results supported the progression of the program into Phase 3 development.
- Other names
- mRNA-based multivalent seasonal influenza vaccine candidate Formulation A
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza mRNA Formulation A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza mRNA Formulation A.